159 related articles for article (PubMed ID: 19562340)
1. Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.
Hendrickson RC; Cicinnati VR; Albers A; Dworacki G; Gambotto A; Pagliano O; Tüting T; Mayordomo JI; Visus C; Appella E; Shabanowitz J; Hunt DF; DeLeo AB
Cancer Immunol Immunother; 2010 Jan; 59(1):113-24. PubMed ID: 19562340
[TBL] [Abstract][Full Text] [Related]
2. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
[TBL] [Abstract][Full Text] [Related]
3. Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte.
Frassanito MA; Mayordomo JI; DeLeo RM; Storkus WJ; Lotze MT; DeLeo AB
Cancer Res; 1995 Jan; 55(1):124-8. PubMed ID: 7528638
[TBL] [Abstract][Full Text] [Related]
4. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).
Uenaka A; Nakayama E
Cancer Sci; 2003 Nov; 94(11):931-6. PubMed ID: 14611667
[TBL] [Abstract][Full Text] [Related]
5. Tumor rejection antigens of the chemically induced BALB/c Meth A sarcoma.
DeLeo AB
Immunol Ser; 1994; 61():31-6. PubMed ID: 8011753
[No Abstract] [Full Text] [Related]
6. possible role of a retrovirus in the expression of tumor-specific antigens of the Meth A sarcoma.
DeLeo AB; Chang KS; Wivel NA; Appella E; Old LJ; Law LW
Int J Cancer; 1982 Jun; 29(6):687-93. PubMed ID: 7107069
[TBL] [Abstract][Full Text] [Related]
7. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
Noguchi Y; Chen YT; Old LJ
Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3171-5. PubMed ID: 7909159
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cloned class I MHC-restricted, CD8+ anti-Meth A cytotoxic T-lymphocytes: recognition of an epitope derived from the Meth A gp110 tumor rejection antigen.
Fassanito MA; Loftus D; De Leo RM; Law LW; Appella E; De Leo AB
Cancer Res; 1994 Aug; 54(16):4424-9. PubMed ID: 7519121
[TBL] [Abstract][Full Text] [Related]
9. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
Tüting T; DeLeo AB; Lotze MT; Storkus WJ
Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
[TBL] [Abstract][Full Text] [Related]
10. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines.
Mayordomo JI; Loftus DJ; Sakamoto H; De Cesare CM; Appasamy PM; Lotze MT; Storkus WJ; Appella E; DeLeo AB
J Exp Med; 1996 Apr; 183(4):1357-65. PubMed ID: 8666894
[TBL] [Abstract][Full Text] [Related]
11. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
[TBL] [Abstract][Full Text] [Related]
12. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
[TBL] [Abstract][Full Text] [Related]
13. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Haicheur N; Bismuth E; Bosset S; Adotevi O; Warnier G; Lacabanne V; Regnault A; Desaymard C; Amigorena S; Ricciardi-Castagnoli P; Goud B; Fridman WH; Johannes L; Tartour E
J Immunol; 2000 Sep; 165(6):3301-8. PubMed ID: 10975847
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a carbohydrate mimicking peptide augments tumor-specific cellular responses.
Monzavi-Karbassi B; Cunto-Amesty G; Luo P; Shamloo S; Blaszcyk-Thurin M; Kieber-Emmons T
Int Immunol; 2001 Nov; 13(11):1361-71. PubMed ID: 11675368
[TBL] [Abstract][Full Text] [Related]
15. Maximizing immune responses: the effects of covalent peptide linkage to beta-2-microglobulin.
Bauer SM; Williams MA; Howell AP; Schwarz E; Smith ES; Zauderer M
Oncol Res; 2008; 17(5):205-16. PubMed ID: 18980017
[TBL] [Abstract][Full Text] [Related]
16. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide.
Godelaine D; Carrasco J; Lucas S; Karanikas V; Schuler-Thurner B; Coulie PG; Schuler G; Boon T; Van Pel A
J Immunol; 2003 Nov; 171(9):4893-7. PubMed ID: 14568970
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer.
Ichiki Y; Takenoyama M; Mizukami M; So T; Sugaya M; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
J Immunol; 2004 Apr; 172(8):4844-50. PubMed ID: 15067062
[TBL] [Abstract][Full Text] [Related]
18. Expression of a shared tumor-specific antigen by two chemically induced BALB/c sarcomas.
Palladino MA; Srivastava PK; Oettgen HF; DeLeo AB
Cancer Res; 1987 Oct; 47(19):5074-9. PubMed ID: 3497717
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.
Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L
J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663
[TBL] [Abstract][Full Text] [Related]
20. Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells.
Muraoka D; Nishikawa H; Noguchi T; Wang L; Harada N; Sato E; Luescher I; Nakayama E; Kato T; Shiku H
Vaccine; 2013 Apr; 31(17):2110-8. PubMed ID: 23499606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
